X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2263) 2263
hematology (1499) 1499
oncology (1467) 1467
index medicus (1324) 1324
male (1283) 1283
female (1279) 1279
middle aged (1133) 1133
adult (1126) 1126
chemotherapy (907) 907
antineoplastic combined chemotherapy protocols - therapeutic use (820) 820
aged (728) 728
high-dose chemotherapy (724) 724
treatment outcome (720) 720
high-dose cytarabine (698) 698
transplantation (695) 695
adolescent (662) 662
cancer (623) 623
bone-marrow-transplantation (553) 553
prognosis (550) 550
non-hodgkins-lymphoma (536) 536
cytarabine - administration & dosage (487) 487
transplantation, autologous (455) 455
acute myelogenous leukemia (450) 450
stem-cell transplantation (442) 442
disease-free survival (420) 420
stem cells (418) 418
combined modality therapy (407) 407
lymphomas (403) 403
care and treatment (397) 397
remission induction (392) 392
high-dose therapy (379) 379
hematopoietic stem cell transplantation (367) 367
therapy (357) 357
high-dose methotrexate (355) 355
retrospective studies (355) 355
recurrence (344) 344
child (336) 336
acute myeloid-leukemia (330) 330
bone-marrow transplantation (327) 327
immunology (312) 312
antineoplastic combined chemotherapy protocols - administration & dosage (293) 293
rituximab (291) 291
survival rate (291) 291
survival analysis (288) 288
medicine & public health (283) 283
young adult (271) 271
antineoplastic combined chemotherapy protocols - adverse effects (266) 266
lymphoma (266) 266
stem cell transplantation (259) 259
salvage therapy (251) 251
risk factors (242) 242
acute myeloid leukemia (240) 240
leukemia (240) 240
survival (239) 239
etoposide - administration & dosage (238) 238
antineoplastic agents - therapeutic use (236) 236
hematopoietic stem cells (236) 236
cytarabine (231) 231
leukemia, myeloid, acute - drug therapy (229) 229
follow-up studies (228) 228
child, preschool (226) 226
hematology, oncology and palliative medicine (214) 214
colony-stimulating factor (210) 210
phase-ii (210) 210
acute lymphoblastic-leukemia (209) 209
hematopoietic stem cell transplantation - methods (209) 209
cyclophosphamide - administration & dosage (205) 205
cyclophosphamide (202) 202
health aspects (201) 201
primary cns lymphoma (199) 199
research (199) 199
etoposide (194) 194
lymphoma, non-hodgkin - therapy (193) 193
acute disease (188) 188
analysis (187) 187
methotrexate (187) 187
cytarabine - therapeutic use (181) 181
pharmacology & pharmacy (175) 175
leukemia, myeloid, acute - therapy (169) 169
children (168) 168
transplantation, homologous (166) 166
relapse (164) 164
trial (164) 164
methotrexate - administration & dosage (163) 163
radiotherapy (160) 160
lymphoma, non-hodgkin - drug therapy (159) 159
acute nonlymphocytic leukemia (151) 151
leukemia, myeloid, acute - mortality (151) 151
bone marrow transplantation (149) 149
transplantation conditioning - methods (148) 148
aged, 80 and over (147) 147
patient outcomes (147) 147
dose-response relationship, drug (146) 146
cytarabine - adverse effects (145) 145
infant (144) 144
drug administration schedule (142) 142
minimal residual disease (142) 142
non-hodgkin's lymphomas (140) 140
autologous stem cell transplantation (138) 138
disease (138) 138
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2706) 2706
German (24) 24
French (10) 10
Russian (10) 10
Spanish (7) 7
Hungarian (2) 2
Japanese (2) 2
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Infection - chemically induced | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article
International Journal of Hematology, ISSN 0925-5710, 4/2019, Volume 109, Issue 4, pp. 418 - 425
Journal Article
Journal Article
by Lei, MQ and Liu, LM and Wang, ZM and Wu, DP
INDIAN JOURNAL OF CANCER, ISSN 0019-509X, 04/2019, Volume 56, Issue 2, pp. 167 - 172
BACKGROUND: Acute myeloid leukemia (AML) patients with non-remission (NR) after the first cycle of standard induction chemotherapy remain a challenge owing to... 
CYTOSINE-ARABINOSIDE | RESISTANT | COLONY-STIMULATING FACTOR | ONCOLOGY | non-remission | CAG | re-induction regimen | Acute myeloid leukemia | SALVAGE REGIMEN | high-dose CAG | induction remission
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 6/2017, Volume 133, Issue 2, pp. 315 - 320
Journal Article
PLOS ONE, ISSN 1932-6203, 04/2013, Volume 8, Issue 4
Background: To determine whether the use of idarubicin+cytarabine (IA) is more effective than the use of daunorubicin+cytarabine (DA) as induction chemotherapy... 
ADULT PATIENTS | MULTICENTER | PUBLICATION BIAS | THERAPY | STATISTICS | MULTIDISCIPLINARY SCIENCES | ACUTE MYELOGENOUS LEUKEMIA | PHASE-III | HIGH-DOSE DAUNORUBICIN | COMBINATION | 1ST COMPLETE REMISSION
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 06/2018, Volume 11, pp. 3425 - 3434
Journal Article
Journal Article
Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 12, pp. 3419 - 3425
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2017, Volume 178, Issue 1, pp. 106 - 111
Summary The efficacy of high‐dose cytarabine (HDCA) plus cyclophosphamide/total‐body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT)... 
BMT/PBSCT | allogeneic transplantation | high‐dose cytarabine | acute lymphoblastic leukaemia | conditioning regimens | high-dose cytarabine | CORD BLOOD TRANSPLANTATION | RISK-FACTORS | PROGNOSIS | MARROW-TRANSPLANTATION | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Japan - epidemiology | Recurrence | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Peripheral Blood Stem Cell Transplantation - adverse effects | Prognosis | Peripheral Blood Stem Cell Transplantation - methods | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Cytarabine - adverse effects | Bone Marrow Transplantation - methods | Cyclophosphamide - adverse effects | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Adult | Female | Registries | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Kaplan-Meier Estimate | Combined Modality Therapy | Cytarabine - administration & dosage | Adolescent | Bone Marrow Transplantation - adverse effects | Aged | Analysis | Mortality | Bone marrow | Adults | Transplantation | Health aspects | Hematopoietic stem cells | Acute lymphatic leukemia | Transplants & implants | Leukemia | Radiation | Bone marrow transplantation | Stem cell transplantation | Blood | Extrapolation | Cyclophosphamide | Cytarabine | Rope | Cord blood | Medical prognosis | Peripheral blood | Irradiation
Journal Article
Hematological Oncology, ISSN 0278-0232, 03/2016, Volume 34, Issue 1, pp. 28 - 35
Journal Article
Pediatrics International, ISSN 1328-8067, 10/2017, Volume 59, Issue 10, pp. 1046 - 1052
Background The combination of fludarabine (Flu), high‐dose cytarabine (Ara‐C) and granulocyte colony‐stimulating factor (G‐CSF; FLAG), with anthracyclines has... 
FLAG‐IDA | minimal residual disease | acute myeloid leukemia | children | relapse | FLAG-IDA | CYTOSINE-ARABINOSIDE | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | RANDOMIZED-TRIAL | HIGH-DOSE CYTARABINE | G-CSF | LIPOSOMAL DAUNORUBICIN | PHASE-II TRIAL | INITIAL THERAPY | PEDIATRICS | Recombinant Proteins - therapeutic use | Recurrence | Drug Administration Schedule | Cytarabine - therapeutic use | Humans | Child, Preschool | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Female | Child | Idarubicin - therapeutic use | Relapse | Chemotherapy | Anthracyclines | Granulocyte colony-stimulating factor | Influenza | Meningitis | Transplantation | Hematopoietic stem cells | Diseases | Cancer | Flow cytometry | Toxicity | Leukemia | Stem cell transplantation | Cerebrospinal fluid | Cytarabine | Granulocytes | Bone marrow | Remission | Bacteria | Colony-stimulating factor | Children | Hematology | Colonies | Myeloid leukemia | Medical treatment | Minimal residual disease | Wilms' tumor | Patients | Lymphoma | Hemopoiesis | Cytometry | Fludarabine | Anthracycline | Fatalities | Adults | Leukocytes (granulocytic) | Acute myeloid leukemia
Journal Article